A year in general thoracic surgery published in the Journal of Thoracic and Cardiovascular Surgery: 2020

Michael Lanuti, MD,a Jules Lin, MD,b Thomas Ng, MD,c and Bryan M. Burt, MDd

The challenges and uncertainties of the year 2020 touched humanity. The entire field of medicine paused, united, and confronted a contagion that has redesigned our professional practices and our lives. This was a time when many surgical specialties stopped operating altogether to redirect resources to the many patients with severe acute respiratory syndrome coronavirus 2, the virus that causes coronavirus disease 2019 (COVID-19). A tireless troop of caregivers, technicians, and innovators, general thoracic surgeons stood on the front line of COVID-19 and cared for the sickest of patients, implementing life-saving and life-sustaining therapies, including extracorporeal membrane oxygenation (ECMO) and tracheostomy. At the same time, we scientifically evaluated the risks of transmission of this virus to our cancer patients and other patients who needed surgical therapies that could not be safely delayed, and wrote the book on how surgery in these patients should be appropriately handled. The Journal of Thoracic and Cardiovascular Surgery (Journal) showcased these and our other contributions to the pandemic during 2020. Perhaps even more notable, is the surgical innovation and advancement of our field that persisted during 2020, despite these challenges. Many of these advances were published in the Journal and are highlighted in the following sections.

LUNG
Lung Cancer: Technique

Several advancements in minimally invasive lung resection can be found in the 2020 volumes of the Journal. Published in the Journal was a prospective multicenter clinical trial by Liberman and colleagues that demonstrated safety in dividing pulmonary artery branches ≤7 mm during lobectomy. Remarkably there were only 3 of 239 vessel sealer failures and only 1 conversion to thoracotomy. A strategy only once imagined, this article and its accompanying video highlight how rigorous surgical investigation can safely usher new surgical technique into practice. Also published in 2020 was an important proceeding by Qiu and colleagues showcasing the evolution of minimally invasive surgery for complex and extended lung resections. The authors presented a propensity-matched analysis of 188 sleeve lobectomies performed robotically, thoracoscopically, or by thoracotomy. No difference in 90-day morbidity or mortality was shown among the 3 groups, with no conversions to thoracotomy in the minimally invasive groups. The robotic technique was associated with decreased blood loss, shorter operative time, and earlier chest tube removal.

Comparative efficacy of stereotactic body radiotherapy (SBRT) and surgery in the treatment of patients with non–small cell lung cancer (NSCLC) remains a highly visible and opinionated theme in the field of thoracic oncology. Until publication of the forthcoming results of modern randomized comparisons of lobectomy with sublobar resection for NSCLC, lobectomy is considered by most to be the gold standard treatment for early-stage NSCLC and is often the operation compared against SBRT. During 2020, the Journal published a rigorous national cancer database (NCDB) study by Wu and colleagues that compared the results of SBRT and other locally invasive ablative strategies.

CENTRAL MESSAGE
During 2020, thoracic surgeons confronted the COVID-19 pandemic head-on while continuing to advance the field of general thoracic surgery.
(eg, thermal ablation) with those of sublobar resection for patients with clinical stage T1 to T2a N0 NSCLC. Propensity-matched analyses demonstrated longer overall survival by sublobar resection that persisted in patients with tumors ≤2 cm.5 This study included a large sample size, and its data were informative; however, it investigated a 10-year period (2004-2014) that was relatively early in the evolution of ablative technologies.

**Immunotherapy, Targeted Molecular, and Adjuvant Therapy**

The field of thoracic oncology has perhaps never been more exciting. Immune checkpoint inhibitors have become standard of care first-line therapy for most patients with metastatic NSCLC and are being rapidly tested in clinical trials for the treatment of early-stage NSCLC in combination with surgery. Several important gaps in the field of immune checkpoint inhibitors therapy for NSCLC were addressed in 2020 in the *Journal*, including the management of immune-related adverse events in our surgical populations by Stiles and colleagues6 and using transcriptomic signatures to stratify tumors into immunogenic or immunoresistant subtypes to potentially explain the variable response to PD-1 blockade in NSCLC by Jang and colleagues.3

Molecular targeted therapy has revolutionized the treatment of patients with metastatic NSCLC and is first-line therapy for patients with stage IV disease who have targetable mutations in oncogenes such as the epidermal growth factor receptor. The multinational randomized Adjuvant Aura (ADAURA) trial was published toward the close of 2020 and already deeply influences the care of patients with surgically resectable epidermal growth factor receptor-mutated lung adenocarcinomas. The primary end point of the trial was disease-free survival for patients with stage II to IIIA disease receiving adjuvant osimertinib. Hazard ratios (0.17-0.39) were among the lowest ever published for a lung cancer adjuvant treatment, and a strong signal was also shown for patients with stage IB disease.5 These exciting data are enhancing the depth of collaboration between medical and surgical thoracic oncology and are actively improving the care of patients with surgically resectable lung adenocarcinomas, particularly in the neoadjuvant space.

Traditional adjuvant therapies remain important in the treatment of patients with surgically resectable NSCLC and several notable studies were published in the *Journal* during 2020. A large NCDB investigation of node-negative large cell neuroendocrine lung cancers (n = 1770) by Wakeam and colleagues demonstrated that chemotherapy in the adjuvant setting was associated with improved overall survival in patients whose tumors were >3 cm in size, that lobectomy was superior to sublobar resection, and that adjuvant radiotherapy did not influence survival. Adjuvant therapy for incompletely resected (R+) stage I through IIIA NSCLC was tackled in another large NCDB study by Edwards and colleagues.10 The authors showed that NSCLC patients with indeterminate margins (defined as margin-positive resection) who were treated with adjuvant chemotherapy or radiation did not experience a survival benefit compared with those who did not have adjuvant therapy.10 These data are expected to inform the R classification in the next staging proposal by the International Association for the Study of Lung Cancer.11

**Biology**

In the current era, it is surprising that we are still faced with uncertainty in whether 2 NSCLCs in the same patient represent stage I or stage IV (separate primaries vs metastatic disease). In a study of multifocal NSCLCs published this year in the *Journal*, Zhong and colleagues12 used next generation DNA sequencing of NSCLC tumors with similar histology and were able to improve the distinction between synchronous primary lung cancers and intrapulmonary metastatic disease. We submit that this approach presages the solution to this unsolved problem in thoracic oncology.

**ESOPHAGUS**

Excitement in endoscopic resection (ER) for esophageal cancer has maintained momentum into and throughout 2020, and the National Comprehensive Cancer Network recommends ER as the preferred treatment for medically fit patients with T1a esophageal adenocarcinoma or squamous cell carcinoma.14 Considering the magnitude of esophagectomy, this recommendation might seem appropriate for elderly patients; however, its application to younger patients must take into account the likelihood of cure by each approach. During 2020, in the *Journal*, Raman and colleagues15 applied multivariable Cox and propensity score matching to a cohort of 831 patients with clinical T1a esophageal cancer and demonstrated that overall survival was similar between ER and esophagectomy, regardless of age. These data provide strong evidence in support of current National Comprehensive Cancer Network guidelines recommending ER as the preferred treatment for all patients with T1a esophageal cancer. Nobel and colleagues provided other eye-opening data on the relationship between age and esophageal cancer in the 2020 issues of the *Journal*. The authors evaluated more than 100,000 patients...
with esophageal adenocarcinoma within the NCDB and showed that the frequency of metastatic disease at the time of diagnosis was highest in the youngest age group, irrespective of tumor grade.16 Without the need for sophisticated statistical analysis, this simple population study should raise awareness and promote a more aggressive clinical evaluation in younger patients with or at high-risk of developing esophageal adenocarcinoma.

The benefits of immunotherapy are now being realized for patients with esophageal cancer, and during 2020, the results of Randomized Trial of Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer (CheckMate 577) were presented at the European Society of Medical Oncology Virtual Congress. CheckMate 577 randomized 794 patients to receive nivolumab versus placebo after trinitrooxidation (ie, chemotherapy/radiation followed by surgery) therapy for esophageal adenocarcinoma or squamous cell carcinoma and reported a doubling of median disease-free survival, corresponding to a 31% risk reduction in recurrence or death, in favor of nivolumab.17 Continued advancement in checkpoint blockade for esophageal cancer is expected during 2021.

Ex-Vivo Lung Perfusion

During 2020, the Journal published a series of investigations that could ultimately expand the available pool of donor lungs, using ex-vivo lung perfusion (EVLP). Tian and colleagues19 reported a meta-analysis of 8 studies totaling 1191 patients evaluating outcomes of EVLP on marginal donor lungs. Although EVLP donors had more abnormal radiographs, worse donor arterial oxygen tension/inspired oxygen fraction, and a longer smoking history, there were no significant differences between EVLP and non-EVLP donor lungs in outcomes that included grade 3 primary graft dysfunction and 1-year survival.39 In another study, Cypel and colleagues20 increased their annual lung transplant activity by 70% using EVLP to assess donor lungs. The authors reported a 70% utilization rate, ranging from 63% for high risk donation after cardiac death to 82% for standard risk donation after cardiac death with maintenance of excellent outcomes.39

Post-EVLP cold ischemic time (>287 minutes) was associated with an increased risk of primary graft dysfunction and 1-year mortality. Whereas EVLP has generally been limited to <24 hours of support, Ozhain and colleagues22 reported preclinical results describing their technique to maintain extracorporeal donor lungs using cross-circulation for 4 days in a porcine model, which may lead to innovative strategies to rehabilitate marginal donor lungs.

Extended Criteria Organs

Another strategy to increase the number of available donor organs is the use of donor lungs from patients with infectious risk factors. In the Journal, Carli and colleagues23 evaluated the influence of the US Public Health Service 2013 broadened definition of increased risk donors on lung transplant outcomes. Investigating the period from 2006 to 2017, the authors noted that the proportion of high-risk donors grew from 8% before 2013, to 22% after 2013, with similar graft and patient survival compared with standard risk infectious donors.23 Following the publication of a clinical trial in the New England Journal of Medicine on the use of heart and lung transplants from hepatitis C-infected donors to uninfected recipients,24 an important invited editorial in the Journal provided expert insight on a strategy of using hepatitis C-infected donor lungs in combination with antiviral agents to expand the pool of donor organs.25 This approach has also been supported in a study that stratified all deceased organ donors from 2015 to 2018 by hepatitis C status using Scientific Registry of Transplant Recipients data and estimated that transplanting lungs from hepatitis C positive donors would lead to an increase of at least 55 donor lungs per year.26

Outcomes and Perioperative Management

In a longitudinal study evaluating outcomes of lung transplantation from 2005 to 2018, Hamilton and colleagues27 showed that survival after lung transplantation in mechanically ventilated patients has improved over time, although preoperative mechanical ventilation remains an important risk factor. Ius and colleagues28 evaluated the long-term outcomes of 311 lung transplant recipients who required intraoperative ECMO. Although these patients had a higher pretransplant risk profile and a more complicated postoperative course, those who survived to hospital discharge had no difference in 5-year survival or chronic lung allograft dysfunction.28 Meanwhile, Hoetzennecker and colleagues29 evaluated routine use of intraoperative ECMO in 159 patients undergoing lung transplantation. They reported grade 3 primary graft dysfunction of only 3% and a 2-year survival of 86% and advocate for the routine use of intraoperative ECMO.29

To address the problem of postoperative deep venous thrombosis in lung transplantation, Jorge and colleagues30 evaluated 1141 patients who received prophylactic
systematic analysis of the paraneoplastic syndromes associated with thymoma and showed that a multimodal treatment approach that includes resection is able to achieve remission of the paraneoplastic syndrome in the majority (76%) of patients, which is associated with improved overall survival.

TRACHEA

During 2020 in the Journal, an important, humbling report in the field of tracheal replacement was published. In this proceeding, the authors analyzed 3 patients who received synthetic tracheal grafts seeded with autologous bone marrow mononuclear cells and showed that these grafts did not become living functional grafts and lead to debilitating complications and death. The publication of these sobering data are considered an important milestone in recalibrating investigational approaches to tracheal replacement in humans.

CONCLUSIONS

Despite the exceptional challenges and uncertainties that we, our patients, and our families have faced this past year from the global COVID-19 pandemic, thoracic surgeons have continued to provide essential care to our patients, including those with lung and esophageal cancer and end-stage lung disease. Our specialty not only continues to thrive, but driven by surgeon innovators, educators, and researchers, our persistence has continued to drive the advancement of our field during 2020.

Conflict of Interest Statement

The authors reported no conflicts of interest.

The Journal policy requires editors and reviewers to disclose conflicts of interest and to decline handling or reviewing manuscripts for which they may have a conflict of interest. The editors and reviewers of this article have no conflicts of interest.

References

5. Wu J, Bai HX, Chan L, Su C, Zhang PJ, Yang L, et al. Sublobar resection compared with stereotactic body radiation therapy and ablation for early stage...


lar profiling of key driver genes improves staging accuracy in multifocal non-


The Journal of Thoracic and Cardiovascular Surgery Volume 162, Number 1 257
A Year in General Thoracic Surgery at JTCVS: Recent Articles from AATS Journals


Commentary: What is now proved was once only imagined: Pulmonary artery branch division with energy. Carrott PW, Burt BM. J Thorac Cardiovasc Surg. 2020;159(1):312-313.


